P3 Health Partners Nevada

p3hp.org

P3 Health Partners (P3) is a patient-centered, physician-led and population health-focused healthcare company. Founded and led by physicians, Sherif Abdou, and Amir Bacchus, P3 is a team of doctors, clinicians and support service professionals with a shared passion and purpose for improving the way patient care is delivered.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

SANA BIOTECHNOLOGY RAISES MORE THAN $700M FOR CELL, GENE THERAPY EFFORTS

Sana Biotechnology | June 23, 2020

news image

A startup company developing in vivo and ex vivo cell therapies has raised a significant chunk of funding for its initial financing from life science and technology venture capital as well as pension plans and others.Seattle-based Sana Biotechnology said Tuesday that it had raised more than $700 million from a wide range of investors, including ARCH Venture Partners, Flagship Pioneering, the Canada Pension Plan Investment Board, Baillie Gifford, F-Prime Capital, the Alaska Permanent Fund, ...

Read More

Cell and Gene Therapy

BONE THERAPEUTICS AND LINK HEALTH SIGN A NON-BINDING TERM SHEET FOR THE GLOBAL RIGHTS OF ALLOB

Bone Therapeutics | November 29, 2021

news image

BONE THERAPEUTICS the cell therapy company addressing unmet medical needs in orthopedics and other diseases, and Link Health Pharma Co., Ltd announce the signing of a non-binding term sheet for the global rights for ALLOB, Bone Therapeutics’ allogeneic bone cell therapy. Subject to the fulfillment of customary condition precedents, Bone Therapeutics and Link Health aim to complete the final agreement and to fully execute it by the end of 2021. This new partnership is s...

Read More

MedTech

AEGLEA BIOTHERAPEUTICS ANNOUNCES EUROPEAN MEDICINES AGENCY VALIDATION OF MARKETING AUTHORIZATION APPLICATION FOR PEGZILARGINASE

Aeglea BioTherapeutics, Inc. | August 19, 2022

news image

Aeglea BioTherapeutics, Inc. a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that a Marketing Authorization Application for pegzilarginase for the treatment of Arginase 1 Deficiency has been submitted to and successfully validated by the European Medicines Agency. The MAA was submitted by Immedica Pharma AB, Aeglea's commercialization partner in Europe and the Middle East. <...

Read More

MedTech

PRECISION COATING ANNOUNCES MERGER WITH N2 BIOMEDICAL TO EXPAND MEDICAL COATINGS PLATFORM

N2 Biomedical | September 20, 2021

news image

Precision Coating, a leading medical coatings service provider to interventional, orthopedic, and advanced surgical markets, is pleased to announce a merger with N2 Biomedical, a Bedford, MA-based company. N2 Biomedical, an Ampersand Capital Partners portfolio company, provides nano-engineered surface treatment and coating services to the medical device industry with its low-temperature Ion Implantation Surface Treatments and Ion Beam Assisted Deposition (IBAD) technologies. ...

Read More
news image

SANA BIOTECHNOLOGY RAISES MORE THAN $700M FOR CELL, GENE THERAPY EFFORTS

Sana Biotechnology | June 23, 2020

A startup company developing in vivo and ex vivo cell therapies has raised a significant chunk of funding for its initial financing from life science and technology venture capital as well as pension plans and others.Seattle-based Sana Biotechnology said Tuesday that it had raised more than $700 million from a wide range of investors, including ARCH Venture Partners, Flagship Pioneering, the Canada Pension Plan Investment Board, Baillie Gifford, F-Prime Capital, the Alaska Permanent Fund, ...

Read More
news image

Cell and Gene Therapy

BONE THERAPEUTICS AND LINK HEALTH SIGN A NON-BINDING TERM SHEET FOR THE GLOBAL RIGHTS OF ALLOB

Bone Therapeutics | November 29, 2021

BONE THERAPEUTICS the cell therapy company addressing unmet medical needs in orthopedics and other diseases, and Link Health Pharma Co., Ltd announce the signing of a non-binding term sheet for the global rights for ALLOB, Bone Therapeutics’ allogeneic bone cell therapy. Subject to the fulfillment of customary condition precedents, Bone Therapeutics and Link Health aim to complete the final agreement and to fully execute it by the end of 2021. This new partnership is s...

Read More
news image

MedTech

AEGLEA BIOTHERAPEUTICS ANNOUNCES EUROPEAN MEDICINES AGENCY VALIDATION OF MARKETING AUTHORIZATION APPLICATION FOR PEGZILARGINASE

Aeglea BioTherapeutics, Inc. | August 19, 2022

Aeglea BioTherapeutics, Inc. a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that a Marketing Authorization Application for pegzilarginase for the treatment of Arginase 1 Deficiency has been submitted to and successfully validated by the European Medicines Agency. The MAA was submitted by Immedica Pharma AB, Aeglea's commercialization partner in Europe and the Middle East. <...

Read More
news image

MedTech

PRECISION COATING ANNOUNCES MERGER WITH N2 BIOMEDICAL TO EXPAND MEDICAL COATINGS PLATFORM

N2 Biomedical | September 20, 2021

Precision Coating, a leading medical coatings service provider to interventional, orthopedic, and advanced surgical markets, is pleased to announce a merger with N2 Biomedical, a Bedford, MA-based company. N2 Biomedical, an Ampersand Capital Partners portfolio company, provides nano-engineered surface treatment and coating services to the medical device industry with its low-temperature Ion Implantation Surface Treatments and Ion Beam Assisted Deposition (IBAD) technologies. ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us